Evidence map›Paper›PMID 37867158›Full record

ArticleJournal of the National Cancer Institute2024

Mental health outcomes in a population-based cohort of patients with prostate cancer.

Siqi Hu, Chun-Pin Chang, John Snyder, Vikrant Deshmukh, Michael Newman, Ankita Date, Carlos Galvao, Benjamin Haaland, Christina A Porucznik, Lisa H Gren and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Siqi HuHuntsman Cancer Institute, Salt Lake City, UT, USA.
Chun-Pin ChangHuntsman Cancer Institute, Salt Lake City, UT, USA.ORCID 0000-0002-0878-997X
John SnyderIntermountain Healthcare, Salt Lake City, UT, USA.
Vikrant DeshmukhUniversity of Utah Health Sciences Center, Salt Lake City, UT, USA.
Michael NewmanUniversity of Utah Health Sciences Center, Salt Lake City, UT, USA.
Ankita DatePedigree and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Carlos GalvaoPedigree and Population Resource, Population Sciences, Huntsman Cancer Institute, Salt Lake City, UT, USA.
Benjamin HaalandHuntsman Cancer Institute, Salt Lake City, UT, USA.
Christina A PorucznikDivision of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Lisa H GrenDivision of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.ORCID 0000-0002-5868-3292
Alejandro SanchezDivision of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA.
Shane LloydDepartment of Radiation Oncology, University of Utah School of Medicine, Salt Lake City, UT, USA.
Brock O'NeilDivision of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA.
Mia HashibeHuntsman Cancer Institute, Salt Lake City, UT, USA.ORCID 0000-0002-6903-2049
University of Utah · USHuntsman Cancer Institute · USIntermountain Healthcare · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Long-Term Adverse Outcomes Among Rural Cancer Survivors in a Population-Based CohortR01CA244326 · NCI · UNIVERSITY OF UTAH · PI CAMP, NICOLA J., HASHIBE, MIA · 2020 to 2024
$2.4M
Population-based Cohort of Endometrial Cancer Survivors in UtahR21CA185811 · NCI · UNIVERSITY OF UTAH · PI HASHIBE, MIA · 2015 to 2016
$356k
Epidemiology of testicular cancer in the Utah populationR03CA159357 · NCI · UNIVERSITY OF UTAH · PI HASHIBE, MIA · 2011 to 2012
$150k
CDC HHSNCI NIH HHS HHSN261201800016CNCI NIH HHS HHSN261201800016INCI NIH HHS P30 CA042014NCI NIH HHS R03 CA159357NCI NIH HHS R21 CA185811NIH HHS R01 CA244326
6 · The paper itself

Abstract

backgroundFew studies have evaluated mental health disorders comprehensively among patients with prostate cancer on long-term follow-up. The primary aim of our study was to assess the incidence of mental health disorders among patients with prostate cancer compared with a general population cohort. A secondary aim was to investigate potential risk factors for mental health disorders among patients with prostate cancer.

methodsCohorts of 18 134 patients with prostate adenocarcinomas diagnosed between 2004 and 2017 and 73470 men without cancer matched on age, birth state, and follow-up time were identified. Mental health diagnoses were identified from electronic health records and statewide health-care facilities data. Cox proportional hazard models were used to estimate hazard ratios. All statistical tests were 2-sided.

resultsThe hazard ratios for mood disorders, including depression, among prostate cancer survivors increased for all follow-up periods compared with the general population. The hazard ratios for any mental illness increased with Hispanic, Black, or multiple races; people who were underweight or obese; those with advanced prostate cancer; and those undergoing their first course cancer treatment. We also observed statistically significantly increased hazard ratios for mental health disorders among patients with lower socioeconomic status (P < .0001) and increasing duration of androgen-deprivation therapy (P = .0348). Prostate cancer survivors had a 61% increased hazard ratio for death with a depression diagnosis.

conclusionProstate cancer diagnosis was associated with a higher risk of mental health disorders compared with the general population, which was observed as long as 10-16 years after cancer diagnosis. Providing long-term mental health support may be beneficial to increasing life expectancy for patients with prostate cancer.

Indexed as

Prostatic NeoplasmsAndrogen AntagonistsHumansMaleOutcome Assessment, Health CareProstateRisk FactorsAndrogen Antagonists

Identifiers

PMID37867158
PMCPMC10919332
OpenAlexW4387855657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.